Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Cohort studyMovement disorders clinical practice· Aug 2026

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Mario Hero, Nadja Grozdanić, Romana Brnić Andrić … Vladimira Vuletić

Read paper

Movement DisordersCohort studyTreatmentQ2IF 2.2

Continuous foslevodopa/foscarbidopa infusion associated with improved motor symptoms at 1 year

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Mario Hero … Vladimira Vuletić

Movement disorders clinical practice · Aug 2026 · Q2 in Neurology

Background

Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24-h delivery of levodopa-carbidopa prodrugs for advanced Parkinson's disease.

Purpose

To characterize 1-year changes in motor, non-motor, autonomic, quality-of-life and sleep outcomes, and in concomitant therapy.

Methods

Retrospective single-center observational study of 32 patients initiated on LDp/CDp between April 2024 and January 2026.

n = 32 patients

Results

motor symptom severity dropped by about a third

More results

Twenty of 32 patients (62.5%) completed 1-year follow-up.

Quality of life improved (p = 0.040), driven by bodily discomfort.

Levodopa-equivalent dose rose by 31.7% while oral dopamine agonist use fell from 70% to 25% (p = 0.004).

“

Conclusion

One year of LDp/CDp was associated with substantial motor benefit and improved quality of life, achieved with higher levodopa equivalent and reduced dopamine agonist use.

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Related papers